Trial · NCT06765902
Immunotherapy Before and After Surgery
NCT06765902, Phase 2, Withdrawn, ImmunityBio, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immunotherapy Before and After Surgery. Trials, record NCT06765902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06765902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immunotherapy Before and After Surgery
- NCT number
- NCT06765902
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- ImmunityBio, Inc.
- Conditions
- High-risk Prostate Cancer
- Interventions
- N-803, ETBX-071, M-CENK
- First posted
- 2025-01-09
- Last updated
- 2026-05-05
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free survival (EFS) | These are assessed from the date of surgery until the occurrence of disease recurrence (EFS) or biochemical recurrence (bRFS), or until the end of the five-year follow-up period. | The length of time from surgery to the first occurrence of disease recurrence (biochemical failure, local/regional recurrence, distant metastasis) or death. |
| Primary | Biochemical recurrence-free survival (bRFS) | These are assessed from the date of surgery until the occurrence of disease recurrence (EFS) or biochemical recurrence (bRFS), or until the end of the five-year follow-up period. | The length of time from surgery to the first evidence of biochemical recurrence (two sequential increases in PSA levels by \>0.2 ng/ml within 3-4 weeks) or death. |
| Secondary | Rate of PSA reduction | Assessed within 6 months post-surgery. | The percentage decrease in PSA levels within six months post-surgery. |
| Secondary | Safety (AEs and SAEs) | Up to 260 weeks. | Assessment of adverse events (AEs), serious adverse events (SAEs), and clinically important changes in laboratory values and vital signs. |
| Other | Quality of life (QoL): | Approximately 13 months | Assessed using validated questionnaires (EPIC-26 and PROMIS). |
| Other | Sexual function | Approximately 13 months | Assessed using the Sexual Health Inventory for Men (SHIM) |
| Other | Changes in immune subsets and antigen-specific immune responses | Approximately 13 months | Measured at baseline and end of treatment. |
| Other | Tumor microenvironment (TME) changes | Approximately 13 months | The tumor microenvironment (TME) is the complex ecosystem of cells, molecules, and extracellular matrix that surrounds and interacts with tumor cells. |
| Other | Circulating tumor DNA (ctDNA) | Approximately 13 months | Levels measured to monitor minimal residual disease. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06765902
GET https://conductscience.org/api/trials/v1/NCT06765902/registered